Sign in to view Johanna’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
New York, New York, United States
Contact Info
Sign in to view Johanna’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
4K followers
500+ connections
Sign in to view Johanna’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Johanna
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Johanna
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Johanna’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
-
Contact Johanna for services
Healthcare Consulting, Project Management, Program Management, Strategic Planning, and Research Skills
Business Info
- Services offered
-
- Healthcare Consulting
- Project Management
- Program Management
- Strategic Planning
- Research Skills
- Work location
- New York, New York, United States
- Work preference
- In person or remote
- Receive free inquiries
- I accept direct messages and business inquiries by anyone on LinkedIn for free, even if we’re not connected. Learn more
Experience & Education
-
NYSE
**** ** ********** & **** ******** ******* *******
-
***
***, ******** **** ** **********
-
*** (****** ******* *****)
**** ** ************ ********** ** *** *********
-
**** **********
****** ** ********** (***) ******* *********
-
******* ************* **********
******** ** ******* (*.*.) *********
View Johanna’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Volunteer Experience
View Johanna’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
People also viewed
-
Eric J. Dimise, PhD
Sector Lead, Healthcare & Life Sciences Capital Markets at NYSE, an ICE Company
Boston, MAConnect -
Jessica J. Federer
New York, NYConnect -
Judy Khan Shaw
New York City Metropolitan AreaConnect -
Alice Zheng
San Francisco, CAConnect -
Lucy Perez
Boston, MAConnect -
Trine Bartholdy
CopenhagenConnect -
Carolyn M. Mazure
Director, Women's Health Research at Yale & Chair, White House Initiative on Women's Health Research
New Haven, CTConnect -
Cassandra Seier
New York, NYConnect -
Jamie White
Health Science Strategist and Advisor
Washington DC-Baltimore AreaConnect -
Paula Senna Ganem
Regional Head of Canada and Latin America Capital Markets at NYSE I instagram: @paulasganem
New York, NYConnect -
Brad Loncar
Lenexa, KSConnect -
Bonnie Hyun
San Francisco Bay AreaConnect -
Sasha Kelemen
New York City Metropolitan AreaConnect -
Sajni Chotai
LondonConnect -
Sharon Kedar, CFA
Washington DC-Baltimore AreaConnect -
Cathy Friedman
United StatesConnect -
Jennifer Hawks Bland
New York City Metropolitan AreaConnect -
Donna Da Cruz Lloyd (She/Her/Ella)
Austin, Texas Metropolitan AreaConnect -
James Potter
Scottsdale, AZConnect -
Coleman Bigelow
New York City Metropolitan AreaConnect
Explore more posts
-
Steve Kraus
As I said right at the start of this week's The Heart of Healthcare Podcast, Shivdev Rao is one of the most exceptional founders I have ever worked with. He is also a great human being. In this week's episode he shares what is it like leading the 🚀 that is Abridge and some awesome life lessons. IMHO this is a great listen for founders building in both the AI and healthcare fields!
573 Comments -
Moorthy Palanki
Investors continue to take their time evaluating investment opportunities as more companies come to market. Jeffrey GrabowEY US Venture Capital. While the market continues its retreat from the highs of 2021, funding for VC-backed companies saw an uptick in Q1 2024, increasing 12% from the $29.4b raised in Q4 2023. Deal volume saw its lowest levels since 2012, as investors scrutinize value propositions and look for clear paths to growth from founders. The only exception to that rule are companies in the artificial intelligence (AI) space. AI-related companies raised $5.6b in Q1, which accounted for 17% of VC investment this quarter. Prior to last year, AI represented 10% of investment on average between 2013–22. https://lnkd.in/gdP6PzXZ
63 Comments -
Sebastian Gensior
Many companies find that navigating the complexities of fundraising can be daunting, but you don't have to do it alone. 📈 2024 Highlights: The number of biotech assets in phase 3 clinical trials has increased compared to 2023. 📊 Trend Over a Decade: Over the past ten years, the number of active biotech products in phase 3 trials has increased fourfold. 🏢 Current Landscape: More than 430 companies are currently funding these trials, reflecting an annual growth rate of 13.7% since 2012 🌟 This growth in late-stage trials is attracting more investment into the biotech sector. Investors are typically more confident in funding companies with advanced clinical assets, leading to potentially higher funding rounds and partnerships Whether you're an investor on the hunt for the next big opportunity or a company in need of funding, this group is here to link you with the right people: https://lnkd.in/ey4v9x3U
196 Comments -
Aleksey N. Krylov, CFA
🎙️Excited to share my recent conversation on "The Business of HLTH" podcast where we delve into the dynamic intersection of finance and #lifesciences. As a #CFO dedicated to advancing the industry, I discuss the nuances of venture investing, M&A, and strategic financial planning that can propel life sciences organizations forward. 🔗Tune in to gain insights into how we at Tialma provide tailored CFO solutions that not only manage but enhance the financial and operational aspects of life sciences companies, ultimately maximizing shareholder value. Whether you're involved in biotech, medtech, or looking to understand the financial intricacies of the industry, this episode offers valuable perspectives. 👉Listen to the episode here: https://lnkd.in/e6Yx8swQ Feel free to connect and discuss how strategic financial leadership can make a measurable impact in the life sciences sector.
113 Comments -
Vic Gatto
Harnessing Proprietary Information for Strategic Healthcare Investments Healthcare investments offer a unique combination of financial returns and the potential for significant social impact. For family offices and discerning investors, navigating this complex landscape requires more than just capital—it demands strategic insights fueled by proprietary information. The Foundation of Strategic Investment: Proprietary Information In the investment world, knowledge is power. This is particularly true in the healthcare sector, where regulatory landscapes, technological advancements, and policy changes can drastically impact the viability and potential of investment opportunities. Access to proprietary information gives investors a critical edge, enabling them to: - Anticipate Market Movements: With insights into healthcare policies and emerging trends, investors can position their portfolios to capitalize on upcoming shifts in the market. - Enhance Due Diligence: Tailored underwriting and due diligence tools grounded in exclusive data can highlight risks and reveal hidden potentials in investment prospects. - Maximize Value Creation: By understanding the intricacies of the US healthcare economy, investors can devise strategies for long-term value creation, rather than short-term gains. Empowering Family Offices Family offices often seek investments that offer both competitive financial returns and the opportunity to create a positive legacy. By refining investment platforms to address the specific needs of these entities, such as instant diversification and upside capture, they can achieve their financial and legacy-driven goals. These platforms can provide: - Market Insights: Curated intelligence that focuses on the most promising healthcare segments. - Educational Resources: In-depth content to deepen the understanding of healthcare technology trends and investment strategies. Building Relationships and Trust Investing is not just about the numbers; it's also about people. To attract and retain high-potential family office prospects, investment platforms must foster empathy and engagement. This involves: - Offering Exclusive Rights: Providing access to follow-on deals and direct investment opportunities with board or advisory roles. - Understanding Emotions: Addressing fears of missing out on prime opportunities due to geographical limitations and dissatisfaction with average investment options. - Creating Community: Facilitating a network of like-minded investors focused on collaborative, high-impact healthcare investments. Harnessing proprietary information is critical for making strategic healthcare investments that offer significant financial returns and contribute to the betterment of society. If you like to learn more about strategic healthcare investments or discuss your specific investment goals and how proprietary information can be leveraged to achieve them? Please feel free to reach out or leave a comment below.
201 Comment -
Bryan Roberts
Advances in AI have driven remarkable progress in both product performance and (therefore?) market interest for health system and physician adoption of digital assistants. With that progress has come lots and lots of start-up noise making it very hard to differentiate amongst the players - everyone says they are awesome and can do everything...so who knows? This is where KLAS shines in the HC IT space - third party, discerning and trusted reviewer of products and services. It is awesome to see that KLAS Research has written an Emerging Company Spotlight on Suki with an Overall Performance Score of 93.2 (which is extraordinary - the 2024 Best in KLAS Software Average is 79.6 out of 100). Ignore the noise and hype - - - the dedicated and innovation driven team at Suki has created the category leader. https://lnkd.in/gYpJQQzr
735 Comments -
Marcelo Claure
Today, I am incredibly excited to announce Claure Group’s investment into K Health, the leading AI Primary Care platform, and partner with Co-founders Allon Bloch and Ran Shaul. As we explore the evolving AI landscape, we've observed significant investments in AI infrastructure—such as energy, semiconductors, data centers, and LLMs—while the application space remains largely untouched. K Health is one of the few companies we've encountered that successfully uses AI to impact millions of lives. They are addressing some of healthcare’s greatest challenges by providing accessibility to faster, higher-quality, lower cost primary care on a large scale. Over the last seven years, K Health has developed the industry’s first AI model for primary care that has been published together with leading research physicians from Mayo Clinic. This has enabled K Health to introduce a virtual AI co-pilot for physicians to handle patient intake. The co-pilot takes patients through a personalized chat, gathers important information from their electronic medical records (EMR), and provides an AI-generated medical report with insights that enable doctors to make high quality diagnosis and treatment decisions. This frees up doctors to focus more on the interaction with patients and helps them make more informed decisions. And because K Health is integrated with health systems, it can efficiently arrange any needed follow-up physical visits, such as diagnostic tests and specialty care. Trusted by leading U.S. health systems, such as Cedars-Sinai, K Health has already been able to increase primary care access by 15%. We look forward to supporting K-Health’s journey to revolutionize the future of healthcare. Read full press release here: https://lnkd.in/eXJAaqmh
38923 Comments -
Gary Goldman MD, DDS, MBA
As physicians, we are committed to improving patient care through clinical excellence. However, there's an often-overlooked avenue where our expertise can significantly impact healthcare innovation: serving as medical advisors for startups. Here are a few reasons why I believe we should engage with the entrepreneurial community 👇 1️⃣ Driving Innovation Forward: Startups are at the forefront of medical technology and services. By contributing our clinical expertise, we can guide these companies to develop solutions that are not only innovative but also practical and patient-centered. 2️⃣ Broadening Impact: While our primary influence is within the confines of our practices or hospitals, working with startups allows us to extend our impact globally. Technologies we help develop could benefit patients worldwide, many of whom could never visit us in person. 3️⃣ Learning and Growth: Engaging with startups exposes us to the latest technologies and business strategies, enriching our understanding beyond the medical field. This cross-disciplinary knowledge can enhance our own practices and the way we approach patient care. 4️⃣ Professional Networking: Collaborating with entrepreneurs and other tech innovators can open new doors. These connections can lead to other advisory roles, speaking opportunities, and even advancements in our own careers. 5️⃣ Financial Opportunities: Often, advising roles come with financial compensation, including equity options. These can provide significant financial benefits, particularly if the startup succeeds. 6️⃣ I urge my fellow clinicians to consider stepping into the role of a medical advisor. Our insights are invaluable, and our participation can be the key differentiator in the success of health-focused innovations. ---- Join our vibrant community of 2,000+ healthtech experts and thought leaders. Comment below or DM me, and I’ll provide you with an invitation to our fast-growing network. 📩
509 Comments -
Christiana Bardon M.D.
Last week, Virginia Li at FirstWord Group led a fantastic discussion of the biotech markets with my public perspectives and the venture financing perspectives of Colleen Feriod Cuffaro of Canaan. A recording of our panel is available at the link below. Takeaways: * We are seeing a pick up in financing volumes but the bar for quality is still very high. It is a also longer process to get through a successful financing, but take the money if you can get it. Dilution is secondary to having a strong syndicate and runway. * Hot areas of investor focus are oncology and autoimmunity. The flavor de jour is applying traditional oncology drugs such as cell therapy and bispecifics to autoimmunity! We have seen early data in myasthenia gravis and lupus. * Gene therapy appears to have cooled off with increasing competition for treating the same disease areas with different modalities such as siRNA. https://lnkd.in/gdtmGDBY
441 Comment -
Dr Fabio D'Agostino
It is not easy to be a disruptor in an intrinsically conservative industry like pharma, but it is so much necessary for the future of medicine. It is a good sign that a key cell and gene therapy player entered the top 10 of CNBC Disruptors (a list where OpenAI has been first for two years in a row). Maybe more biotech disruptors in the top ten of this list in the future? For now, well done ElevateBio! With more than $ 1.25B raised, key R&D Partnerships with Pharma including Novo Nordisk, there is great potential to see new genetic medicines in areas like cancer and autoimmune diseases #celltherapy #genetherapy #ElevateBio #CNBCDisruptors #BiotechInnovation #FutureOfMedicine
31 -
Venture Capital Journal
The convoluted structure of the healthcare industry and unique challenges of technology adoption give VCs with experience as clinicians and operators an advantage, says Zoi Capital co-founder Dr. Ronald Razmi. Read the story here to learn more: https://okt.to/Cxl1Lo #VCJ #VentureCapital #ArtificalIntelligence #EmergingManagers #Healthcare #NorthAmerica
1 -
TrialKey
Opyl (ASX: OPL) Executive Chairman, Saurabh Jain, was recently featured on the Innovation and Leadership podcast with Jess Larsen. Jess, co-founder of a biotech venture capital firm focused on preventive medicines and longevity, and founder of Graystoke Investments, and Graystoke Networks, brings his unique perspective to the table. 🔉 Listen now: https://lnkd.in/g7Dhsu6r In this insightful conversation, Saurabh shares how TrialKey is revolutionising clinical trials through advanced AI and predictive analytics. They discussed how TrialKey unlocks hidden insights from over 400,000 clinical trials by analysing them across 700 variables using Natural Language Processing to convert unstructured data into actionable intelligence. 📈 A key discussion point was how trial phase data showing success or failure is a critical inflection point for mid to smaller #biofund stock prices. TrialKey's insights can help #biotech and #biopharma investors navigate which stocks are likely to increase in value. 🔎 They also explored the use of TrialKey in analysing Plasminogen Activator Inhibitor-1 (PAI-1) and competitors' efforts on conditions like Crohn’s disease. By understanding how you rank against competitors in probability of success and using #TrialGen to design optimal trials, TrialKey provides a significant advantage. They highlighted how TrialKey is the market leader in AI prediction and optimisation software, thanks to our comprehensive analysis of the most variables, detailed data presentation, insights, and trial simulations. One key takeaway from Jess during the episode is that while you can always find good scientists, good drug developers are harder to come by. The groundbreaking technology of TrialKey could revolutionise the pharmaceutical industry and accelerate the development of life-saving drugs. The sheer volume of medical information makes it impossible for any one person to know it all, which is why an AI tool like TrialKey is revolutionary. Book a demo: https://lnkd.in/g9rJtUBm Marketing, investor, and speaking enquiries: bernice.averion@opyl.ai #clinicaltrials #AI #Pharma #investments #asx #opyl #trialkey
8 -
Jacqueline Mejia, PhD
Activation Capital is seeking #startups to participate in their NEW Frontier BioHealth program. APPLY NOW! https://lnkd.in/dBiSQuNZ - ❗ Application Deadline: June 17, 2024 - 🏁 Program Kickoff: August 8, 2024 - 🎉 Program End: November 22, 2024 - 💻 Location: All virtual except for three in-person events. Travel costs will be covered! -💰 Investment: We do not invest and we do not take any equity. - 🔬 Startups transitioning #lifesciences innovations from research to commercialization, particularly those originating from academic or federal research labs, are highly encouraged to apply. - 🌟 Startups with a clear commercialization path, some initial funding (dilutive or non-dilutive), a full-time founder, licensing, optioning, or the ability to demonstrate control of their IP are highly encouraged to apply. More About the Program: -Website: https://lnkd.in/dBiSQuNZ -Apply Here: https://lnkd.in/dAFb_XpE -Meet with Jackie to learn more: https://lnkd.in/dF3-Ga3h #medicaldevice #pharma #biotech #diagnostic
402 Comments -
Grigory Borisenko
Looking back at the past 30 years, I remember myself doing science about 55-60 hours a week, and then helping venture capitalists and biotech start-ups about 70-80 h/week. Usually unsatisfied, sometimes exhausted, but pleased overall. This overexciting workaholism was somehow interrupted last year. I had less work and a lot of mountaineering, - climbed about 5.5 Chomolungma attitudes during the year. It feels like I have reached the stage at which it is a time to start sharing experiences and understanding of the universe. This week, I started to share by publishing an analytic report at SeekigAlpha about TG Therapeutics. This small biotech company has developed a third-to-market anti-CD20 mAb for the treatment of multiple sclerosis (MS). Along with the company, this report briefly touches upon current treatments for MS, the competitive landscape of therapeutics, and the uncertainties surrounding the development of new BTK inhibitors. https://lnkd.in/drAFx9vt
10
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More